Natural History of Acquired and Inherited Bone Marrow Failure Syndromes

  • STATUS
    Recruiting
  • End date
    Feb 4, 2041
  • participants needed
    1000
  • sponsor
    National Heart, Lung, and Blood Institute (NHLBI)
Updated on 4 October 2022

Summary

Background

Bone marrow failure diseases are rare. Much is known about the diseases at the time of diagnosis, but long-term data about the effects of the diseases and treatments are lacking. Researchers want to better understand long-term outcomes in people with these diseases.

Objective

To follow people diagnosed with acquired or inherited bone marrow failure disease and study the long-term effects of the disease and its treatments on organ function.

Eligibility

People aged 2 years and older who have been diagnosed with acquired or inherited bone marrow failure or Telomere Biology Disorder. First degree family members may also be able to take part in the study.

Design

Participants will be screened with a medical history, physical exam, and blood tests. They may have a bone marrow biopsy and aspiration. For this, a large needle will be inserted in the hip through a small cut. Marrow will be drawn from the bone. A small piece of bone may be removed.

Participants may also be screened with some of the following:

Cheek swab or hair follicle sample

Skin biopsy

Urine or saliva sample

Evaluation by disease specialists (e.g., lung, liver, heart)

Imaging scan of the chest

Liver ultrasounds

Six-Minute Walk Test

Lung function test

Participants will be put into groups based on their disease. They will have visits every 1 to 3 years. At visits, they may repeat some screening tests. They may fill out yearly surveys about their medicines, transfusions, pregnancy, bleeding, and so on. They may have other specialized procedures, such as imaging scans and ultrasounds.

Participation will last for up to 20 years.

...

Description

Study Description: This study will allow for the long term follow up of patients with acquired and inherited bone marrow failure, both treated and untreated.

Objectives

Primary Objective

The primary objective is to characterize disease and treatment related long-term outcomes in subjects with inherited or acquired marrow failure.

Secondary Objectives

  1. Rates of disease progression requiring intervention
  2. Determine overall survival
  3. Determine event free survival in subjects who receive treatment
  4. Genetic or molecular biomarker to predict the long-term outcomes/early diagnosis in SAA and disease progression in other marrow failures.
  5. Determine effects of pregnancy, viral infections, and vaccinations on disease course
  6. Determine rates of both hematologic and solid organ malignancies
  7. For Telomere Biology Disorders (TBD) cohort, assess the systemic impact of the disease including lung function, liver function, immunodeficiency, endocrine disorders, vascular disorders, and cardiovascular disease
  8. For diseases with a genetic cause, determine the differences in clinical phenotype between different mutations causing the syndrome (example within TBD)
  9. Family genetic studies to determine the incidence and penetrance of specific gene mutations within one family

Tertiary/Exploratory Objectives

  1. Genomic analysis (including whole exome or whole genome sequencing) to seek a potentially disease-causing mutations in subjects who meet the clinical phenotype for inherited disease but do not harbor a known mutation using sequencing
  2. Serial assessment of hematopoiesis and immune activity as it relates to clinical course
    Endpoints

Primary Endpoints:

Cohort 1 (SAA): Rate of relapse and clonal evolution in previously treated subjects.

Cohort 2 (Other marrow failure): Rate of progression (cytopenias or clonal evolution) requiring therapeutic intervention.

Cohort 3 Telomere Biology Disorders (TBD): Development of cytopenias, lung disease or liver disease, or (if present at baseline)

characterization, and rate of progression of cytopenias, lung disease or liver disease in TBD subjects and looking at their overall contribution to morbidity and mortality.

Cohort 4 Inherited Bone Marrow Failure (IBMF): Rate of progression to transfusion dependent marrow failure, marrow failure requiring therapeutic intervention (such as medical therapy or HSCT) or the progression to hematological or solid malignancy.

Secondary Endpoints:

Cohort 1 (SAA):

  1. Response to treatment at 3 and 6 months and rates of relapse
  2. Overall survival
  3. Type and severity of additional medical diagnoses
  4. Rates of clinically significant paroxysmal nocturnal hemoglobinuria (PNH)
  5. Rates, timing, and treatment of abnormal iron status (iron overload or deficiency)
  6. Rates and outcomes of pregnancy, and rate and treatment of abnormal menses
  7. Rates of drug induced complications
  8. Incidence of vaccination and rates of relapse following administration

Cohort 2 (Other marrow failure):

  1. Treatment response
  2. Development of PNH and occurrence of symptoms, or need for therapy
  3. Overall survival

Cohort 3 (TBD):

  1. Overall survival
  2. Response to treatment in terms of improvement of cytopenias, or slower progression of lung or liver disease or fibrosis
  3. Development of hematological or solid organ malignancy
  4. Presence of an immunodeficiency or abnormal lab values (immunoglobulin or lymphocyte profile)
  5. Presence of an endocrine disorder or abnormal hormonal levels
  6. Presence of a vascular abnormality
  7. Presence of an abnormal ECG or ECHO. Incidence of IHD over time
  8. Presence, development of or rate of progression of cytopenias,lung disease, and liver disease compared between TBD causing mutations
  9. Presence of TBD mutation in a family member and its association with cytopenias, short telomeres, and evidence of lung or liver involvement. Presence, development of or rate of progression of cytopenias, lung disease, and liver disease compared between family members with the same mutation
  10. Genomic analysis using whole exome sequencing or whole genome sequencing to look for potentially disease causing variants in subjects who meet the clinical phenotype for TBD but do not have a known mutation

Cohort 4 (IBMF):

  1. Overall survival
  2. Treatment response
  3. Development of hematological or solid organ malignancy
  4. New medical diagnosis and its relationship to any treatment received
  5. Record PNH incidence in IBMF as defined by a clone size of >1% in granulocytes
  6. Determine the incidence of iron overload, its course with any IBMF treatments, and its response to chelation therapy
  7. Record the outcomes of pregnant subjects
  8. The presence of viral and bacterial infections and correlation to worsening cytopenias. Presence of worsening cytopenias after vaccination
  9. Presence of IBMF mutation in a family member and its association with cytopenias, and other clinical phenotypes
  10. Genomic analysis using whole exome sequencing or whole genome sequencing to look for potentially disease causing variants in subjects who meet the clinical phenotype for TBD but do not have a known mutation

Details
Condition Severe Aplastic Anemia, Telomere Biology Disorders, Inherited Bone Marrow Failure Syndromes
Clinical Study IdentifierNCT05012111
SponsorNational Heart, Lung, and Blood Institute (NHLBI)
Last Modified on4 October 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

To be eligible to participate in this study, an individual must meet all of the following
criteria. Subjects and their family members who undergo screening but ultimately do not
meet criteria for cohorts 1-5 will be removed from the study. Subjects may forgo screening
and sign directly onto cohorts 1-5 if they meet criteria based on either prior NIH testing
or external examinations. Family members will only be asked to be screened for
participation onto this study after confirmation of eligibility by an affected participant
Cohorts 1-4
Diagnosis of acquired or inherited bone marrow failure or ineffective hematopoiesis or
TBD (see below for cohort 3 specific criteria)
Age >=2 years
Ability and willingness to come to the NIH CC for consultation and testing
Ability of subject or Legally Authorized Representative (LAR) to understand the
investigational nature of the protocol and their willingness to sign a written
informed consent document
For cohort 3 - TBD
Presence of a pathogenic, likely pathogenic, or known family mutation in a telomere
maintenance gene
OR
If mutation negative or VUS, telomere length <10^th percentile in lymphocytes with at least
two clinical features: 1) cytopenia (Hb <10g/dL or ANC <1.5x10^9 or platelets<100), 2)
documented liver fibrosis by histology OR abnormal liver US / fibro scan consistent with
fatty liver or fibrosis), 3) documented pulmonary fibrosis by histology
Cohort 5
Age >= 2 years
First degree family member with a known or suspected inherited bone marrow failure
syndrome from a patient enrolled on this or another NIH protocol as determined by a PI
or AI
Ability and willingness to safely provide blood, buccal swab, or fibroblasts for
testing as stated by subject
Ability of subject or Legally Authorized Representative (LAR) to understand the
investigational nature of the protocol and the willingness to sign a written informed
consent document

Exclusion Criteria

Post HSCT (except if cohort 3 - TBD)
MDS/AML on chemotherapy (patients with hypoplastic MDS who have received or are on
erythropoietin stimulating agent (ESA), granulocyte colony-stimulating factor (GCSF)
or immunosuppressive treatment will not be excluded). Subjects in Cohort 3 with TBD
can be seen if they have received chemotherapy for MDS/AML
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note